Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641248 | 1.00 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21640516 | 1.00 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21640590 | 0.80 | LMNA (0.37) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21641189 | 0.77 | EPHX1 (0.41) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| Trifluoroacetic Acid SCHEMBL21640515 | 0.75 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| Trifluoroacetic Acid SCHEMBL21641246 | 0.75 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21750359 | 0.75 | LMNA (0.37) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21640213 | 0.75 | LMNA (0.37) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21640648 | 0.75 | LMNA (0.37) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL21639847 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | NPC1 4631/4885RAB9A 103/4885SMN1; SMN2 3320/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | NPC1 4687/4885RAB9A 88/4885SMN1; SMN2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.